T cell–activating bispecific antibodies in cancer therapy

Asaad Trabolsi, Artavazd Arumov, Jonathan H Schatz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Effector lymphocytes are multifunctional cells of the immune system that promote cytolysis of pathogen-infected cells and nascent tumors. Tumors must learn to evade effectors and employ a wide variety of mechanisms to do so. Bispecific Abs (BsAbs) are an emerging cancer immunotherapy approach seeking to re-engage either T effectors or NK cells with malignant cells. Possessing specificity for effector cells on one end and a tumor Ag on the other, these molecules work by attracting effectors to the target cell to build an immunologic synapse and induce tumor cell killing. The BsAb blinatumomab, for example, has specificity for the T cell–activating cell surface protein CD3 and the B cell Ag CD19. The only BsAb with regulatory approval currently, blinatumomab is used in the treatment of relapsed or refractory B cell acute lymphoblastic leukemia. Many additional BsAbs are in preclinical development, however, targeting many different tumor types. The variety of potential effector cells and cancer Ags, along with potential combination therapies, make BsAbs an active area of drug development. In this review, we discuss cancer recognition by the immune system and structural and mechanistic aspects of BsAbs. We summarize key steps in preclinical development and subsequent translation to medical practice. Future directions for BsAbs include combinations with a wide variety of both immunologic and nonimmunologic therapies. Defining their optimum clinical use is at early stages.

Original languageEnglish (US)
Pages (from-to)585-592
Number of pages8
JournalJournal of Immunology
Volume203
Issue number3
DOIs
StatePublished - Aug 1 2019

Fingerprint

Bispecific Antibodies
Neoplasms
Therapeutics
Immune System
B-Lymphocytes
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Natural Killer Cells
Immunotherapy
Synapses
Membrane Proteins
Lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

T cell–activating bispecific antibodies in cancer therapy. / Trabolsi, Asaad; Arumov, Artavazd; Schatz, Jonathan H.

In: Journal of Immunology, Vol. 203, No. 3, 01.08.2019, p. 585-592.

Research output: Contribution to journalArticle

Trabolsi, Asaad ; Arumov, Artavazd ; Schatz, Jonathan H. / T cell–activating bispecific antibodies in cancer therapy. In: Journal of Immunology. 2019 ; Vol. 203, No. 3. pp. 585-592.
@article{cf292a9803654498aaf885402d820a12,
title = "T cell–activating bispecific antibodies in cancer therapy",
abstract = "Effector lymphocytes are multifunctional cells of the immune system that promote cytolysis of pathogen-infected cells and nascent tumors. Tumors must learn to evade effectors and employ a wide variety of mechanisms to do so. Bispecific Abs (BsAbs) are an emerging cancer immunotherapy approach seeking to re-engage either T effectors or NK cells with malignant cells. Possessing specificity for effector cells on one end and a tumor Ag on the other, these molecules work by attracting effectors to the target cell to build an immunologic synapse and induce tumor cell killing. The BsAb blinatumomab, for example, has specificity for the T cell–activating cell surface protein CD3 and the B cell Ag CD19. The only BsAb with regulatory approval currently, blinatumomab is used in the treatment of relapsed or refractory B cell acute lymphoblastic leukemia. Many additional BsAbs are in preclinical development, however, targeting many different tumor types. The variety of potential effector cells and cancer Ags, along with potential combination therapies, make BsAbs an active area of drug development. In this review, we discuss cancer recognition by the immune system and structural and mechanistic aspects of BsAbs. We summarize key steps in preclinical development and subsequent translation to medical practice. Future directions for BsAbs include combinations with a wide variety of both immunologic and nonimmunologic therapies. Defining their optimum clinical use is at early stages.",
author = "Asaad Trabolsi and Artavazd Arumov and Schatz, {Jonathan H}",
year = "2019",
month = "8",
day = "1",
doi = "10.4049/jimmunol.1900496",
language = "English (US)",
volume = "203",
pages = "585--592",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "3",

}

TY - JOUR

T1 - T cell–activating bispecific antibodies in cancer therapy

AU - Trabolsi, Asaad

AU - Arumov, Artavazd

AU - Schatz, Jonathan H

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Effector lymphocytes are multifunctional cells of the immune system that promote cytolysis of pathogen-infected cells and nascent tumors. Tumors must learn to evade effectors and employ a wide variety of mechanisms to do so. Bispecific Abs (BsAbs) are an emerging cancer immunotherapy approach seeking to re-engage either T effectors or NK cells with malignant cells. Possessing specificity for effector cells on one end and a tumor Ag on the other, these molecules work by attracting effectors to the target cell to build an immunologic synapse and induce tumor cell killing. The BsAb blinatumomab, for example, has specificity for the T cell–activating cell surface protein CD3 and the B cell Ag CD19. The only BsAb with regulatory approval currently, blinatumomab is used in the treatment of relapsed or refractory B cell acute lymphoblastic leukemia. Many additional BsAbs are in preclinical development, however, targeting many different tumor types. The variety of potential effector cells and cancer Ags, along with potential combination therapies, make BsAbs an active area of drug development. In this review, we discuss cancer recognition by the immune system and structural and mechanistic aspects of BsAbs. We summarize key steps in preclinical development and subsequent translation to medical practice. Future directions for BsAbs include combinations with a wide variety of both immunologic and nonimmunologic therapies. Defining their optimum clinical use is at early stages.

AB - Effector lymphocytes are multifunctional cells of the immune system that promote cytolysis of pathogen-infected cells and nascent tumors. Tumors must learn to evade effectors and employ a wide variety of mechanisms to do so. Bispecific Abs (BsAbs) are an emerging cancer immunotherapy approach seeking to re-engage either T effectors or NK cells with malignant cells. Possessing specificity for effector cells on one end and a tumor Ag on the other, these molecules work by attracting effectors to the target cell to build an immunologic synapse and induce tumor cell killing. The BsAb blinatumomab, for example, has specificity for the T cell–activating cell surface protein CD3 and the B cell Ag CD19. The only BsAb with regulatory approval currently, blinatumomab is used in the treatment of relapsed or refractory B cell acute lymphoblastic leukemia. Many additional BsAbs are in preclinical development, however, targeting many different tumor types. The variety of potential effector cells and cancer Ags, along with potential combination therapies, make BsAbs an active area of drug development. In this review, we discuss cancer recognition by the immune system and structural and mechanistic aspects of BsAbs. We summarize key steps in preclinical development and subsequent translation to medical practice. Future directions for BsAbs include combinations with a wide variety of both immunologic and nonimmunologic therapies. Defining their optimum clinical use is at early stages.

UR - http://www.scopus.com/inward/record.url?scp=85069610744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069610744&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1900496

DO - 10.4049/jimmunol.1900496

M3 - Article

C2 - 31332079

AN - SCOPUS:85069610744

VL - 203

SP - 585

EP - 592

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 3

ER -